Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
14 hedge funds and large institutions have $1.63M invested in Sonnet BioTherapeutics in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
75% more funds holding
Funds holding: 8 → 14 (+6)
60% more capital invested
Capital invested by funds: $1.02M → $1.63M (+$610K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$291K |
| 2 |
VF
Virtu Financial
New York
|
+$164K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$114K |
| 4 |
Bank of New York Mellon
New York
|
+$50.6K |
| 5 |
Jane Street
New York
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $575K | +$25.3K | +4 | +4% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $306K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $255K | +$291K | +46 | New |
|
|
VF
4
Virtu Financial
New York
| $146K | +$164K | +26 | New |
|
|
5
T. Rowe Price Associates
Baltimore,
Maryland
| $101K | +$114K | +18 | New |
|
|
ASN
6
Advisory Services Network
Atlanta,
Georgia
| $61K | +$6.32K | +1 | +10% |
|
|
7
Bank of New York Mellon
New York
| $46K | +$50.6K | +8 | New |
|
|
8
Jane Street
New York
| $39K | +$44.3K | +7 | New |
|
9
Geode Capital Management
Boston,
Massachusetts
| $35K | – | – | – |
|
|
MSFS
10
Main Street Financial Solutions
Newtown,
Pennsylvania
| $24K | – | – | – |
|
|
SC
11
Scholtz & Company
Stamford,
Connecticut
| $23K | +$25.3K | +4 | New |
|
12
UBS Group
Zurich,
Switzerland
| $10K | – | – | – |
|
|
IA
13
IFP Advisors
Tampa,
Florida
| $4K | +$6.32K | +1 | New |
|
14
Morgan Stanley
New York
| $3K | – | – | – |
|
|
TRCT
15
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
16
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$34K | -6 | Closed |
|
SONN Hedge Fund Activity: Q1 2021 in Review
14 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2021, worth a combined $1.63M — up 60% from $1.02M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SONN positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $291K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $34K sold.
- 14 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2021, up from 8 in Q4 2020.
- Funds reported $1.63M of Sonnet BioTherapeutics stock for Q1 2021, up 60% quarter-over-quarter.
- 7 funds opened new Sonnet BioTherapeutics positions in Q1 2021 and 1 closed out, a net change of +6 holders.
- The largest Sonnet BioTherapeutics buyer in Q1 2021 was Citadel Advisors, an estimated $291K added.
- The largest Sonnet BioTherapeutics seller in Q1 2021 was Susquehanna International Group, an estimated $34K sold.
Based on aggregated 13F filings for Q1 2021.